Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03522844 · ClinicalTrials.gov registry record · Phase 4
Treatments for Anxiety: Meditation and Escitalopram
A Phase 4 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 4
- Development phase
- 276
- Enrollment target
NCT03522844: Completed Phase 4 study, sponsored by Georgetown University.
NCT03522844 is a Phase 4 study that has completed, run by Georgetown University. The registered enrollment target is 276 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03522844, a Phase 4 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 276 participants
- Enrollment target
Study Summary
We propose the first randomized, controlled study to assess the comparative effectiveness of Mindfulness-Based Stress Reduction (MBSR) with a medication for anxiety disorders. We will use escitalopram, gold-standard SSRI treatment for patients with anxiety disorders, and will examine the comparative effectiveness of the two treatments on anxiety symptoms and other outcomes important to patients.
Primary Outcome
The CGI is a measure of symptom severity and is rated by a clinician
Interventions
- DRUG Escitalopram
- OTHER Mindfulness-Based Stress Reduction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2018-06-18 |
| Est. Completion | 2022-01-05 |
| Phase | Phase 4 |
What the finished NCT03522844 record still lists
NCT03522844 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Escitalopram is the first listed.
NCT03522844 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03522844 about?
NCT03522844 is a clinical study titled "Treatments for Anxiety: Meditation and Escitalopram". We propose the first randomized, controlled study to assess the comparative effectiveness of Mindfulness-Based Stress Reduction (MBSR) with a medication for anxiety disorders. We will use escitalopram, gold-standard SSRI treatment for patients with anxiety disorders, and will examine the comparative...
What is the current status of trial NCT03522844?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 276 participants. The study started on 2018-06-18. Estimated completion is 2022-01-05.
What interventions are being tested in trial NCT03522844?
The interventions under investigation include: Escitalopram (DRUG), Mindfulness-Based Stress Reduction (OTHER).
Who is sponsoring clinical trial NCT03522844?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03522844's enrollment target sits among peer trials
276 310th of 2000 higher than 1,690 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI